title: Erythema multiforme with tumour necrosis factor inhibitors: a class effect?
authors.forename: T
authors.initials: T
authors.lastname: Kain
authors.forename: D
authors.initials: D
authors.lastname: MacGregor
authors.forename: R R C
authors.initials: RR
authors.lastname: Buchanan
authors.forename: J P
authors.initials: JP
authors.lastname: de Jager
authors.forename: L
authors.initials: L
authors.lastname: Schachna
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004892:Erythema Multiforme / Q000139:chemically induced*; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D013167:Spondylitis, Ankylosing / Q000188:drug therapy; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab